

Welcome to the exciting
world of

OBJ LIMITED



Providing innovative solutions to the Pharmaceutical, Cosmetic,
Skincare, Oral health and Consumer products Industries



Disclaimer

This Presentation has been prepared by OBJ Limited (ABN 72 056 482 636) (OBJ or the Company). This Presentation contains summary information about OBJ and its activities current as at the date of this Presentation. The information in this Presentation is of general background and does not purport to be complete or to comprise all the information that a shareholder or potential investor in OBJ may require in order to determine whether to deal in OBJ shares. It should be read in conjunction with OBJ's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), which are available at www.asx.com.au. This document is not a prospectus or a product disclosure statement under the Corporations Act (Cth) 2001 (Corporations Act) and has not been lodged with the Australian Securities and Investments Commission (ASIC).

Past performance information given in this Presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This Presentation contains certain "forward-looking statements". The words "expect", "should", "could", "may", "will", "predict", "plan", "scenario", "forecasts", "anticipates", "outlook" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Such forward-looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. There can be no assurance that actual outcomes will not

differ materially from these forward-looking statements, and there are risks associated with the Company and the industry (including those set out below) which may affect the accuracy of the forward-looking statements. The Company does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this presentation, or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

This document may not be released or distributed in the United States. This Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. Securities in the Company have not been, and will not be, registered under the U.S. Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States unless the securities are registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration.

To the maximum extent permitted by law, OBJ and its respective advisers and affiliates, directors, officers and employees make no representation or warranty, express or implied, as to the accuracy, reliability or completeness of information in the Presentation.

Corporate Information


KEY STATISTICS (30.01.2015)

ASX Code	OBJ
Current Share Price	\$0.085
52 Week High	\$0.13
52 Week Low	\$0.032
Shares on Issue	~1,650m
Market Capitalisation	~\$140m
Net Cash (31 Dec 2014)	~\$4.7m
Performance Rights	(various hurdles) 88m
Cash Burn per month	~\$140k

SHAREHOLDER BREAKDOWN

Top 5 Shareholders	7%
Top 20 Shareholders (inc top 5)	21%
Management	6%

12 MONTH SHARE PRICE PERFORMANCE



Company Highlights

- Biotechnology/Industrial company focused on product performance enhancement through Physical rather than Chemical means
- Major international partners including P&G, COTY, GSK & Pfizer
- Multi-product development agreement with P&G
- First product under the P&G PDA developed and launched
- Term Sheet for second product development & license with COTY Group executed
- Successful clinical validation and TGA approval of internally developed BodyGuard product
- Signed Exclusive Evaluation & Option Agreement with P&G for BodyGuard



The Science in Diamagnetic Repulsion

Driving performance through physical rather than chemical science




Diamagnetic Repulsion Demonstration

Video not visible in printed version

First Product Launch - SK-II Eye Wand

Launched in South Korea, Hong Kong, Taiwan with Japan, China and ROW to follow



Video not visible in printed version

Consumer Response Driving New Markets



Supported by Celebrity Promotions



Procter & Gamble (P&G)

- Multi-product Product Development Agreement (PDA) provides a framework for P&G brands to work with OBJ
- Three initial work plans formed the PDA, the first of which is now converted to the first Licensing Agreement and launched as SK-II Eye Wand in several Asian markets
- The two remaining work plans are progressing with the next now entering clinical phase
- Two additional work plans from new P&G brands, inspired by the success of SK-II have now been added to the PDA
- Development programs now advancing for the next generation of SK-II innovations based on OBJ technology





Procter & Gamble (cont.)

- The first launch of OBJ's licensed product in South Korea in October 2014, followed by Hong Kong and Taiwan in December – Initial production runs sold out within days
- Launch plans for Japan, China, rest of Asia and the world underway
- SK-II Wave II development now well advanced
- Additional applications within other SK-II-like franchises under discussion with P&G in the USA
- An excellent relationship with solid and expanding potential

COTY Philosophy



- Following excellent results in the clinical trial of 2013, and consumer testing and market research, COTY entered into a Product Development and Licensing Term Sheet with OBJ in 2014
- First application for OBJ's powered technology being commercialised subject to pre-launch milestones
- Dermaportation was OBJ's original technology and for which patents have been granted for Europe and the USA
- Royalties will be payable on both the Device and on associated Philosophy formulation sales

COTY Philosophy

(cont.)



- The Term Sheet covers the development and licensing of the handset optimised for Philosophy's formulation
- The fully funded development phase will see OBJ work with the Philosophy group to develop and optimise the handset design for consumer and claims studies
- The major terms of the license, including royalties on device and formulations sales and limitations on market territories, channels and exclusivity have already been agreed
- Another excellent relationship and second licensee for OBJ



Managing joint pain by removing the cause, not the symptoms



BodyGuard

First of OBJ's internally developed advanced products

- Designed to support and enhance joint function to avoid ageing and degeneration during exercise or following injury
- Clinically proven to be effective in an initial Australian study
- Approved by the TGA in Australia
- Global regulatory assessment completed by major international consulting experts
- Formal Clinical and Consumer evaluation studies about to commence





BodyGuard


P & G

- Executed Exclusive Evaluation & Option Agreement with P&G's NBC group
- P&G is to conduct market research, consumer acceptance studies and price sensitivity modeling
- BodyGuard to conduct clinical study with UQ, led by Prof Tony Wright and conducted by Prof Bill Vincenzino
- P&G and BodyGuard to pool data and knowhow
- P&G granted an exclusive Option to negotiate a worldwide musculoskeletal PDA and License Agreement



BodyGuard Product Platform

PowerDots



SuperTube



KneeGuard

GlaxoSmithKline

(Analgesics)

- Successful completion of Phase I & II formulation development programs
- Next steps to be determined once GSK/ Novartis JV roles are better defined

(Medicated Skincare)

- Substantial interest from GSK /Stiefel Dermatology group
- Meetings scheduled for first quarter in the USA

(Oral Healthcare)

- Following 5 successful studies with GSK over 7 years, informal feedback from recent fluoride retention study indicates insufficient enhancement from manual toothbrush following 30 second application per region. OBJ considers extended application time may be necessary for efficacy in manual application
- Electric toothbrush heads with high motional speeds are considered to provide greatly increased delivery potential
- Discussions to be held during the first quarter of 2015 with two major multi-national companies regarding access to OBJ's technology for application into electric toothbrushes.



Additional Internal Development Programs

Following the success of BodyGuard, OBJ has established two new divisions to utilise OBJ technology in new product sectors rather than out-licensing



Surface Penetration

To develop advanced skin hygiene, surface antiseptic and surface penetration product platforms for retail, hospital and industrial applications



E-Skin

To develop a range of personalised skincare platforms and e-commerce system for the professional cosmetic and skincare sectors

OBJ Growth

- Expanded laboratory team and analytical capabilities to cope with the increased demand of our client base
- Realigned BD programs to reflect increased activity in USA and Asia
- Increasing Administration and QA programs to further enhance ability to exceed customer needs
- Redesigned Website to increase OBJ's visibility to prospective partners in new business areas



Thank You

OBJ LIMITED

ABOUT
CAPABILITIES
SCIENCE & TECHNOLOGY
INDUSTRIES & MARKET SECTORS
PARTNERING
SHAREHOLDER RELATIONS
CONTACT US

WELCOME TO OBJ LIMITED

Leader In Magnetic Enhanced Delivery Solutions

OBJ is the leading developer of magnetic, micro-array drug and ingredient delivery technologies. OBJ has over 100 years of combined expertise in transdermal, perioral, appendageal and sub-surface drug and ingredient delivery and associated product development.

OBJ provides partnering services and product solutions for next generation products in:

- Transdermal and Intra-Dermal Drug Delivery
- Therapeutic and Dermatological skincare
- Cosmetic and non-medicinal active ingredient with special focus on anti-aging and peptide delivery
- Oral Health strips, advanced tooth brush technologies and mouth guards
- Haircare solutions utilizing enhanced brushes and applicators
- High Penetration surface hygiene technologies
- Fabric and Carpet cleaning technologies
- Advanced industrial surface interface systems

OBJ Company Presentation **OBJ diamagnetic demonstration**

ABN 72 056 482 636
294 Oxford St Leederville
WA 6007 Australia
Telephone +61 8 9443 3011
Facsimile +618 9443 3866
Email info@obj.com.au
Sitemap
© 2014 OBJ Limited
Admin Login
Developed by Creative Forte